Previous Close | 0.1327 |
Open | 0.1365 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.1365 - 0.1365 |
52 Week Range | 0.1220 - 1.0900 |
Volume | |
Avg. Volume | 31,829 |
Market Cap | 16.864M |
Beta (5Y Monthly) | 0.94 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1140 |
Earnings Date | Mar 21, 2022 - Mar 25, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.00 |
Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general meeting of shareholders held on May 13, 2022 (the "Meeting"). A total of 42,387,564 common shares, representing approximately 34.31% of the Company's issued and outstanding shares were represented at the meeting.
Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of high-value molecules traditionally derived from plants, has released its financial and operating results for the three months ended March 31, 2022, reporting significant progress to its operational platform and strong liquidity.
Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of high-value molecules traditionally derived from plants, announces expanded production capacity with a new manufacturing partnership and progress with respect to its Generally Recognized as Safe ("GRAS") determination.